Sigachi Industries up 8.0% on Rs 290 cr warrant issue to fund API expansion

Sigachi Industries Ltd was last traded at Rs 32.93, up 8.0% in Monday’s session, after the company filed the detailed notice for an Extra-Ordinary General Meeting (EGM) seeking shareholder nod for a large preferential issue of convertible warrants.

The move in the stock appears to be driven less by the mechanics of the EGM itself and more by what the notice reveals about the company’s capital-raising plan, growth ambitions in Active Pharmaceutical Ingredients (APIs) and excipients, and the extent of promoter skin in the game.

What Sigachi has put on the table

According to the EGM notice dated August 22, 2026 (pages 2–3):

• The company plans to issue up to 11,00,00,000 (Eleven Crores) convertible warrants of face value Re. 1 each.
• Each warrant will be issued at Rs. 26.40 per warrant, including a premium of Rs. 25.40 per share (page 3 and page 9).
• Each warrant carries the right to subscribe to one equity share at Rs. 26.40 per share on conversion (page 3).
• The total issue size aggregates to Rs. 290,40,00,000 (Rupees Two Hundred Ninety Crores and Forty Lakhs Only) (pages 3 and 10).

This is a sizeable raise relative to the company’s current equity base. The notice on page 11 shows the pre-issue paid-up equity capital at 38,21,17,010 shares of Re. 1 each, rising to 49,21,17,010 shares on a fully diluted basis if all 11 crore warrants are converted.

Why the market is focusing on growth, not just dilution

The filing is explicit about how the money will be deployed. The explanatory statement on page 9 breaks the Rs. 290.40 crore into three buckets:

• Rs. 190.40 crore for "Acquisition / Expansion of Active Pharmaceutical Ingredients (API) and Excipients including Croscarmellose Sodium (CCS)", with a tentative utilisation timeline of 3 years.
• Rs. 60.00 crore for working capital, with a 2-year utilisation timeline.
• Rs. 40.00 crore for general corporate purposes, also over 2 years.

For a specialty chemicals and excipients player, that first line item is the strategic heart of the plan. The company is signalling a multi-year expansion in APIs and excipients, including CCS, backed by a clearly earmarked capex pool rather than a vague “growth” label.

That helps explain why the stock moved up despite the clear dilution overhang:

• Page 11 shows promoter shareholding rising from 36.69% pre-issue to 43.73% post-issue on a fully diluted basis, while non-promoters fall from 63.31% to 56.27%.
• Within that, the key promoter, Mr. Amit Raj Sinha, is slated to receive 7,50,00,000 warrants (page 4 and page 13), taking his holding from 1,40,00,000 shares (3.66%) to 8,90,00,000 shares (18.09%) on full conversion (page 13).

In other words, the dilution is real, but the controlling shareholder is taking a large chunk of the new paper at the same price as outside investors. That combination of a defined growth use-case and strong promoter participation is often read as a positive signal in the mid-cap and small-cap space.

Pricing, valuation signals and why Rs 26.40 matters

The notice also lays out how the issue price was set, which the market will scrutinise closely when judging whether the deal is “cheap” or “expensive”.

On page 18, the company explains that the minimum price under SEBI’s preferential issue rules was computed off the National Stock Exchange data, as NSE had higher trading volume in the 90 days before the relevant date.

Key pricing disclosures (page 18):

• 90 trading days volume-weighted average price (VWAP): Rs. 22.72.
• 10 trading days VWAP: Rs. 26.31.
• Minimum permissible issue price under Regulation 164(1): Rs. 26.31 per share.

Sigachi has chosen to price the warrants at Rs. 26.40, just above that regulatory floor and the independent valuation:

• The valuation report (page 19) pegs the price of the equity share at Rs. 26.31 per share.
• The company proposes an issue price of Rs. 26.40 per share, marginally higher than the valuation and the SEBI-computed minimum.

The fact that the issue is not being done at a steep discount to the regulatory floor, and that the promoter is subscribing at this price, appears to be one of the reasons the stock reacted positively. The market often discounts deeply underpriced preferential issues as value-destructive for existing shareholders; here, the pricing is tight to a formal valuation and VWAP benchmarks.

Structure, timelines and governance safeguards

Several structural elements in the notice also help frame the risk-reward for investors:

• Conversion window: Warrant holders can convert by paying the remaining 75% of the issue price any time up to 18 months from the date of allotment (page 12). If they do not exercise within this period, the entitlement lapses and the upfront 25% is forfeited.
• Upfront payment: An amount equivalent to 25% of the issue price per warrant must be paid before allotment (page 12), ensuring some capital commitment from allottees from day one.
• No change in control: The company explicitly states on page 17 that there will be "no change in control or change in management" as a result of the preferential issue, and that it does not trigger an open-offer obligation under SEBI’s takeover regulations.
• Monitoring agency: Because the issue size exceeds One hundred Crores Rupees, Sigachi has appointed a SEBI-registered credit rating agency as a monitoring agency to track utilisation of the proceeds (page 21). The agency will report quarterly until 100% of proceeds are used.

These features collectively reduce some of the governance and execution concerns that can accompany large preferential issues in smaller companies.

Why the stock moved: reading the filing against the price action

The EGM notice itself is procedural – it sets out that the first EGM of FY 2026–27 will be held on 15th September, 2026 at 11.00 a.m. via video conferencing (page 2), with 08.09.2026 as the cut-off date for e-voting (page 1 and page 25). Those mechanics do not move stocks.

What appears to have driven the 8.0% rise to Rs 32.93 is the clarity and scale of the growth plan and the alignment of interests:

• A clearly quantified Rs 190.40 crore push into APIs and excipients over three years.
• A substantial working capital buffer of Rs 60.00 crore, which can support higher throughput once capacity ramps up.
• Promoter participation via 7.5 crore warrants, lifting promoter holding to 43.73% on a fully diluted basis (page 11), at a price aligned with regulatory and valuation benchmarks.

At the same time, the filing underscores real risks that the market will continue to weigh:

• Dilution: Total shares outstanding could rise from 38,21,17,010 to 49,21,17,010 (page 11) if all warrants convert.
• Execution: The company has given itself up to 3 years to deploy the bulk of the capex (page 9), and the filing does not provide revenue, profit or margin projections linked to this investment.
• No financial guidance: The notice is silent on expected returns on the API/excipient expansion; investors must infer potential upside from the sector context rather than explicit targets.

Given that the stock’s 8.0% move came after the detailed contours of the preferential issue were laid out, the reaction looks like a market vote that, on balance, the growth optionality and promoter commitment outweigh the dilution and execution risks – at least at current levels.

What the filing does not tell us

For all its detail on structure and compliance, the EGM notice is not a business plan. It does not disclose:

• Any historical or projected revenue or profit numbers.
• Margins, return ratios or payback periods for the planned API and excipient investments.
• Specific acquisition targets or project locations.

Investors therefore have to connect the dots themselves between this capital raise and future earnings. The strong price reaction suggests the market is currently willing to give Sigachi the benefit of the doubt, but how the stock trades from here will depend on how quickly the company converts this capital into visible growth.